Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.
The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human ...
White button mushrooms promoted antitumor activity among men with prostate cancer, according to results of an ongoing ...
Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...
Jan. 22, 2025 — Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone ...
DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...
The approval of datopotamab deruxtecan, a novel TROP2-directed antibody drug conjugate, marks a major therapeutic milestone and provides patients with metastatic breast cancer a new treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback